Abstract
AbstractEarly diagnosis and treatment of hepatocellular carcinoma (HCC) remain major challenges. Significant efforts have been made to find new approaches to address these issues. Ferric‐tannic nanoparticles (FTs) have emerged as promising tools for targeting the early phase of hepatocarcinogenesis due to their preferential accumulation in preneoplastic liver lesions. In this study, the therapeutic potential of FTs is demonstrated in early‐stage hepatocarcinogenesis in rats. FTs inhibit the progression of early hepatocarcinogenesis, reducing hepatic nodules, preneoplastic foci (glutathione S‐transferase placental (GST‐P) form‐positive foci), and HCC cell proliferation. The therapeutic effects of FTs appear to be mediated by inhibiting cell proliferation through the activation of immune responses. FTs show promise as novel immunomodulators or therapeutic agents for the treatment of early‐stage HCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
